Copyright © 2022 Binhui Bio All Rights Reserved
鄂ICP备16007335号-1Legal Terms
Partners
Viral Vector Platform
Nucleic Acid Platform
Protein Platform
Cell Therapy Platform
Binhui's Viral Vector Platform
The highly scalable oHSV2-based platform1)Deletion of neurotoxic factor ICP34.5, promote selective viral replication in tumor cells, enhance safety.
2)Deletion of immune suppressive gene ICP47, promote antigen presentation and viral replication, enhance anti-tumor efficacy.
3)Insert GM-CSF, to induce stronger, durable and specific anti-tumor immune responses.
Viral Vector Platform Progress
Candidates
Indication
Pre-clinical
IND
Dose Escalation (Phase I)
Dose Extension (Phase II)
Pivotal Study (Phase III)
Melanoma
GBM
mCRC
Others
Melanoma with αPD-1 failure
mCRC
Sarcoma
Solid tumors(IIT)
Solid tumors
Solid tumors
BH-RACE platform of nucleic acid drug
Product process
S-protein trimer mRNA vaccine
Monkeypox vaccine
Rabies vaccine
Neo-antigen tumor vaccines
Heterologous tumor mRNA vaccines
In vivo CAR-T
In vivo CAR-NK
Nucleic Acid Platform Progress
Candidates
Indication
Pre-clinical
IND
Dose Escalation (Phase I)
Dose Extension (Phase II)
Pivotal Study (Phase III)
Solid tumors
Vaccine/Anti-muscle spasm/Anti-wrinkle
Unique protein purification process
Protein Platform Progress
Candidates
Indication
Pre-clinical
IND
Dose Escalation (Phase I)
Dose Extension (Phase II)
Pivotal Study (Phase III)
/
Human and pets
Cell Therapy Platform Progress
Candidates
Indication
Pre-clinical
IND
Dose Escalation (Phase I)
Dose Extension (Phase II)
Pivotal Study (Phase III)
Malignant pleural and abdominal effusions(IIT)
Malignant pleural and abdominal effusions